Quality of Life in Children and Adolescents with Cystic Fibrosis: Implications for Optimizing Treatments and Clinical Trial Design

Author： Abbott J. Gee L.

Publisher： Adis International

ISSN： 1174-5878

Source： Pediatric Drugs, Vol.5, Iss.1, 2003-01, pp. : 41-56

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging Treatments in Cystic Fibrosis

By Jones Andrew M. Helm Jennifer M.

Drugs, Vol. 69, Iss. 14, 2009-10 ,pp. : 1903-1910

Adis International

Access to resources Recommend Favorite

Emerging drug treatments for cystic fibrosis

By Zeitlin Pamela L

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 2, 2007-05 ,pp. : 329-336

Informa Healthcare

Access to resources Recommend Favorite

Emerging drug treatments for cystic fibrosis

By Zeitlin Pamela L

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 2, 2003-11 ,pp. : 523-535

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of Ibuprofen in Children with Cystic Fibrosis

By Han E.E. Beringer P.M. Louie S.G. Gill M.A. Shapiro B.J.

Clinical Pharmacokinetics, Vol. 43, Iss. 3, 2004-01 ,pp. : 145-156

Adis International

Access to resources Recommend Favorite

Leukotriene Receptor Antagonists in Children with Cystic Fibrosis Lung Disease: Anti-Inflammatory and Clinical Effects

By Schmitt-Grohé Sabina

Pediatric Drugs, Vol. 7, Iss. 6, 2005-01 ,pp. : 353-363

Adis International

Access to resources Recommend Favorite